You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥一哥出手回購,創新藥ETF上升
格隆匯 05-16 13:02

格隆匯5月16日丨恒瑞醫藥今日盤中大升,升幅近5%。消息面上,5月15日創新藥龍頭恒瑞醫藥公吿,公司擬以6億元-12億元回購股份,用於員工持股計劃。回購價格為不超過70.14元/股。

恒瑞醫藥帶動創新藥ETF上升,建信基金創新藥50ETF、銀華基金創新藥ETF、廣發基金創新藥ETF 、創新藥ETF易方達、工銀瑞信基金創新藥產業ETF、摩根基金創新藥企ETF、南方基金創新藥指ETF上升,本週以來升幅超3%。

創新藥ETF跟蹤的是中證創新藥產業指數,該指數選取主營業務涉及創新藥研發的上市公司作為待選樣本,按照市值排序選取不超過50家最具代表性公司作為樣本股,反映創新藥產業上市公司的整體表現,成分股主要來自生物醫藥、化學制藥、醫療服務行業,整體研發支出佔比遠高於市場平均水平。

目前市場上有7只創新藥ETF,其中銀華基金創新藥ETF最新規模84.71億,廣發基金創新藥ETF 最新規模34.54億,是市場上規模最大的兩隻創新藥ETF

近兩年醫藥股下跌,創新藥ETF今年年線收綠。醫藥看似低迷,實則默默發力,今年以來,資金不斷入場抄底,部分醫藥ETF份額創出新高。

廣發基金稱2023年較為看好創新藥行業的投資機會,一方面,近年醫保常態化等政策持續鼓勵創新藥發展,醫保談判釋放創新藥温和降價信號。另一方面,國內藥企積極推動國產創新藥進入醫保,未來將帶來較大放量預期。此外,創新藥企業加速出海腳步,不少國內上市公司的創新藥研發在國內乃至世界均處於領先地位,未來國內龍頭創新藥企業有望迎來爆發。

鵬華基金經理金笑表示從2023年開始醫藥會是一個大年,2023、2024年都會有層出層出不窮的醫藥投資機會,看好醫藥底層原因主要有幾個方面:

第一,有增量資金不斷入場。醫藥板塊從2021年二季度達到高點,一直到2022年的三季度,連續跌了一年半。但是,醫藥基金即便是在最悲觀的時候,都在淨申購,醫藥總盤是在不斷的增長,現在大概有4000多億的規模。隨着醫藥進入上升趨勢,增量資金的入場速度還會提升,所以這個板塊一定要重視。

第二,醫藥是一個不斷有增量資金入場的核心主賽道,但全市場基金對醫藥的持倉反而在大幅度的砍倉。從2021年的二季度一直砍到2022年的三季度,全基對醫藥的持倉只有4%,這是近10多年以來最低的水位,其中還包括很多大的白馬股。這個現象是非常值得關注的,這也代表了醫藥板塊的底部。從去年四季度最新披露的數據中可以看到,拐點已經出現了,全基對醫藥的持倉從4%上升到了5%左右。做一個大膽的判斷,未來三年醫藥新週期開啟,全市場基金對於醫藥的持倉會從低點的4%逐漸上升到15%的高位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account